Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 27:18:1615-1624.
doi: 10.2147/CCID.S517656. eCollection 2025.

Novel Approach for Evaluating the Effectiveness of Biological Drugs in Patients with Plaque Psoriasis: Real-World Experience of a Single-Centre Study in Poland

Agnieszka Kimak-Pielas  1   2 , Ewa Robak  1   2 , Radosław Zajdel  3   4 , Agnieszka Żebrowska  1   2
Affiliations

Novel Approach for Evaluating the Effectiveness of Biological Drugs in Patients with Plaque Psoriasis: Real-World Experience of a Single-Centre Study in Poland

Agnieszka Kimak-Pielas et al. Clin Cosmet Investig Dermatol. .

Abstract

Introduction: Biologic therapies have revolutionized psoriasis treatment, offering targeted interventions that significantly improve outcomes for patients with moderate to severe forms of the disease. In Poland, biologic treatment for psoriasis is funded through the National Health Service's B.47 program, available since 2013.

Aim: This study aimed to perform a retrospective analysis of the effectiveness of biologic treatments during the first year of therapy in patients with plaque psoriasis, treated with biologic agents under the B.47 program at a single center in Poland.

Methods: Medical records of patients with plaque psoriasis who were enrolled in the National Health Service's B.47 drug program at the dermatology department between January 1, 2013, and August 2, 2024, were reviewed. This retrospective chart review utilized secondary data from these records. Ultimately, 159 patients totaling 300 drug-periods were enrolled to the study.

Results: Six distinct patterns of treatment response emerged within the first year. Anti-IL-17AF therapy achieved complete remission (PASI-100) in the shortest time (53.8 days vs 101.7 days for a total population, p<0.05). While treatment effectiveness did not differ between bio-naive and non-bio-naive patients overall, repeated exposures to anti-TNF and anti-IL-12/23 therapies were associated with a diminished clinical response.

Conclusion: The study highlights the critical importance of strategic selection of the treatment to optimize long-term outcomes.

Keywords: PASI; biological drugs; effectiveness; plaque psoriasis; psoriasis severity.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Study design.
Figure 2
Figure 2
Changes in psoriasis severity during the first year of treatment, assessed using: (A) DLQI, (B) BSA, and (C) PASI scales. Measurements were taken at the following time points: baseline (treatment initiation), 2 months (±30 days), 4 months (±30 days), 7 months (±30 days), and 12 months (±30 days).
Figure 3
Figure 3
Six patterns of drug effectiveness in the first year of therapy, using PASI-75 as the threshold for defining treatment success.
Figure 4
Figure 4
Comparison of drug effectiveness in the studied group in % (N=300).
Figure 5
Figure 5
Time to achieve PASI-100 (in days) for the analyzed drugs.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. NHS Drug Programs. Available from: https://www.gov.pl/web/zdrowie/programy-lekowe. Accessed 12, September 2024.
    1. Kimak-Pielas A, Robak E, Zajdel R, Zebrowska A. Demographics, Disease Characteristics, and Treatment Patterns of Patients with Plaque Psoriasis Treated with Biological Drugs: the Experience of a Single-Centre Study in Poland. J Clin Med. 2024;13(24):7647. doi: 10.3390/JCM13247647 - DOI - PMC - PubMed
    1. Reich K, Mrowietz U, Radtke MA, et al. Drug Safety of Systemic Treatments for Psoriasis: results from The German Psoriasis Registry PsoBest. Arch Dermatol Res. 2015;307(10):875. doi: 10.1007/S00403-015-1593-8 - DOI - PMC - PubMed
    1. Mahil SK, Wilson N, Dand N, et al. Psoriasis Treat to Target: defining Outcomes in Psoriasis Using Data from a Real‐world, Population‐based Cohort Study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR). Br J Dermatol. 2020;182:1158–1166. doi: 10.1111/BJD.18333 - DOI - PMC - PubMed
    1. Geifman N, Azadbakht N, Zeng J, et al. Defining Trajectories of Response in Patients with Psoriasis Treated with Biologic Therapies. Br J Dermatol. 2021;185(4):825–835. doi: 10.1111/BJD.20140 - DOI - PubMed

LinkOut - more resources